Astrocytoma Idh-wildtype

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-04-07
Clinical Trial Update: ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial [Phase 1]
Phase 1 trial update for ERAS-801 in IDH-wildtype glioblastoma or astrocytoma with EGFR amplification or mutation; enrolling currently.